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The relationship between the secretion of interleukin 10 (IL-10) and nitric oxide
(NO) by hamster peritoneal macrophages and their cytotoxic effects on the cells
of those two melanoma lines was studied.
The nonuniform reaction of macrophages from hamsters bearing two trans-
plantable melanoma lines has been observed. An increase in the cytotoxicity of
macrophages from hamsters bearing the amelanotic melanoma line was accom-
panied by an inverse correlation between IL-10 and NO secretion. Such a rela-
tionship was not found in the case of macrophages from animals bearing the
native-melanotic melanoma line. It is suggested that the phenotypical changes
of melanomas connected with their progression modified the cytotoxic and secre-
tory activity of the macrophages with regard to IL-10 and NO.
key words: NO, interleukin 10, cytotoxicity macrophages, transplantable
melanomas
INTRODUCTION
A number of reports have indicated that IL-10
can modulate antitumour immunological reactivity
of macrophages [1, 8, 20, 26, 27]. Ealier observa-
tions underlined the fact that IL-10 produced by
macrophages suppressed the immunological re-
sponse to tumour [17, 19, 20, 22].
Most recent studies have shown that this cytokine
is the inhibitor of the growth and metastasis of
tumours [1, 9, 10, 15, 25].
It has also been described that IL-10 inhibits the
production of many cytokines, i.e.TNF-a, NO which
are involved in the cytotoxic reaction [21, 24, 27].
Moreover, it has been pointed out that although the
pleiotropic action of IL-10 is known, its role in vivo
in  organisms bearing tumours has not been well
explained [1, 25].
Our ealier investigations showed that the biologi-
cal features of transplantable melanomas and their
progression influenced changes in the cytotoxic ac-
tivity of peritoneal macrophages [14]. Therefore, in
a continuation of our study on changes in macroph-
age reactivity induced by two transplantable mela-
nomas of the same origin but differing in the growth
rate, cell differentiation [2, 4] and immunogenicity
[11], it was particularly interesting to find out to what
extent the cytotoxic effect of peritoneal macroph-
ages is related to IL-10 and NO secretion. Also, it is
advisable to establish  if the IL-10 secretion by mac-
rophages is modified in animals bearing two mela-
128
Folia Morphol., 2002, Vol. 61, No. 3
noma lines in comparison with the secretion of this
cytokine without any activation.
MATERIAL AND METHODS
Animals
Male Syrian (golden) hamsters, Mesocricetus
auratus Waterhouse, 3–4 months old, were pur-
chased from the Central Animal Facilities of the
Silesian Medical University, Katowice, Poland. The
animals were then conventionally reared at the
Department’s animal facility and fed standard diet
and tap water ad libitum. The experimental proce-
dures were approved by the Animal Ethics Commit-
tee at the Medical University of Gdańsk and con-
formed to the National Health and Medical Research
Council’s guide for the care and use of laboratory
animals.
Transplantable melanomas
The tumours were transplantable melanotic and
amelanotic melanomas. The melanotic melanoma
line (Ma) derived from a spontaneous melanoma of
the skin, which appeared spontaneously in a breed
of golden hamsters in 1959. The amelanotic mela-
noma line (Ab) originated from the melanotic form
by a spontaneous alteration into a more aggresive
tumorogenic phenotype in which loss of pigment
was accompanied by an acceleration of growth,
a lower degree of differentiation [2, 4], changes in
antigenicity and immunogenicity [11].
The hamsters were injected with a suspension of
melanoma tissue obtained by mincing in a glass
homogenizer. The tumour tissue was injected sub-
cutaneously into the flank region in an amount of
200 mg of melanotic per hamster and 50 mg of
amelanotic melanoma per hamster. Hamsters with
transplanted melanotic melanoma were used for the
experiments 21–24 days after the inoculation, and
those with amelanotic melanoma 10–12 days after
inoculation. Differences in the quantity of transplant-
ed tumours and the duration of time after inocula-
tion were adjusted to the rate of growth of these
two melanoma lines.
Animals consisting of 3–4 hamsters were used in
each experimental group (hamsters with Ma and Ab
line and  normal animals).
Isolation of melanotic and amelanotic
melanoma cells
Melanoma cells were isolated from solid tumours
by a non-enzymatic method, described previously to
obtain single-cell suspension [3]. The suspension
consisted of 95–98% of viable cells estimated by test
with trypan blue.
Macrophages
Peritoneal exudate cells were induced by inject-
ing animals with 10 ml of 2.98% thioglycolate me-
dium (Gibco), and five days later were washed out
of the peritoneal cavity by means of 0.9% NaCl. They
were then isolated by the method described previ-
ously [28]. Peritoneal macrophages were thus har-
vested from control and experimental groups.
Preparation of supernatants from macrophages
Macrophages at a concentration of 1 ¥ 106/ml
(for cytotoxicity assay) and 3 ¥ 106/ml (for ELISA as-
say) were incubated in RPMI 1640 (culture medium,
BioMed, Lublin) (without FCS-foetal calf serum) for
1h in 6-well plates (Sarstedt) and then nonadherent
cells were removed, fresh medium was added and
incubated for 24 h (for NO estimation) and 48 h (for
IL-10 estimation and cytotoxic activity), respectively.
Assay of supernatant cytotoxic activity
Cytotoxic activity of supernatants against the cells
of transplantable melanomas was measured by
a colorimetric method with MTT (3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide) (Sig-
ma-Aldrich, 5 mg/ml PBS) [18]. Briefly, melanoma
cells suspended in 500 ml of the medium [RPMI 1640
(BioMed Lublin, 10% FCS (GIBCO), antibiotics] at
a concentration of 4 ¥ 105/ml were incubated for 18 h
with 500 ml of supernatants at 37oC. Cells incubated
in medium without supernatants were used as
a control sample.
Cytotoxicity of the supernatant was measured
spectrophotometrically using absorbance at 570 nm.
% cytotoxicity was calculated as follows:
absorbance of samples with supernatants
% cytotoxicity = 100 –   —————————————————————— ¥ 100
absorbance of samples without supernatants
IL-10 determination by ELISA test
Level of IL-10 in the supernatant of macrophages
was determined by the Quantikine mouse IL-10 im-
munoassays (Research and Diagnostic Systems, Min-
neapolis, MN, USA) which is a solid-phase ELISA. The
assay was performed as described in the instructions.
Absorbance at 450 nm was determined on a micro-
plate reader (BioRad). Sensitivity limit of the ELISA
for IL-10 was 4.0 pg/ml. Samples were assayed in
triplicate.
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Assay of nitre oxide concentration
Nitric oxide (NO), quantified by the accumula-
tion of nitrite (NO2–) (as a stable end product) in the
24 hr macrophage supernatants, was measured by
a microplate assay method according to Ding et al.
[7]. Briefly, 50 ml samples of each supernatant per
well were transferred to a 96-well microassay plate
(Nunc) and incubated with an equal volume of modi-
fied Griess reagent (Sigma-Aldrich) at room tempera-
ture for 10 min. Absorbance at 540 nm was deter-
mined in a BioRad microplate reader. Nitric oxide
concentration was calculated from a sodium nitrite
(NaNO2, Sigma-Aldrich) standard curve. In all experi-
ments nitrite contents in wells containing medium
without macrophages were also measured and
substracted from experimental values.
Data are expressed as nmol nitrite/1 ¥ 106 cells/ml.
Statistical evaluation
Group data expressed as mean ± SD were statis-
tically estimated by nonparametric Mann-Whitney
U test by the STATISTICA program. The p value of
less than 0.05 was considered to represent a statis-
tically significant difference.
 
The results obtained regarding the relation be-
tween the  IL-10 and NO contents in macrophage
supernatants, and the cytotoxicity of these superna-
tants in control macrophages (from animals without
melanomas, which have no contact with melanoma
cells), and macrophages from animals bearing trans-
plantable melanomas, are listed in Figure 1. We found
a statistically significant increase (in comparison with
control macrophages) of IL-10 content in the super-
natants from macrophages of animals bearing mel-
anotic melanoma and a statistically significant de-
crease of IL-10 secretion by macrophages from ani-
mals with amelanotic melanoma. At the same time
the supernatant of control macrophages was found
to contain the lowest amounts of NO when the con-
centration of IL-10 was at a medium level. In animals
bearing transplantable melanomas the cytotoxic ac-
tivity of macrophages increased and it was accompa-
nied by changes in the content of the IL-10 and NO.
Statistical analysis of the results obtained con-
cerning the cytotoxic activity indicated a statistically
corroborated increase in the cytotoxic activity of su-
pernatants from macrophages of animals bearing
the amelanotic melanoma line.
The cytotoxicity was about 79%, while the cy-
totoxic activity of macrophages from animals with
the native — melanotic melanoma line was 57%
(p < 0.001, Fig. 1).
Simultaneously, we observed that macrophages
from animals bearing melanotic melanoma showed
a marked (in comparison with the control), 60% in-
crease of IL-10 content and only about 18% higher
secretion of NO.
On the other hand, after an amelanotic mela-
noma line transplantation an increase in macroph-
age cytotoxic activity was followed by a decrease in
the secretion of IL-10, whose content in the super-
natants was 45% lower than in the control macroph-
ages and 66% lower than in macrophages from ani-
mals bearing melanotic melanoma, also with a statis-
tically significant increase in NO secretion, which was
60% higher than in the control (p < 0.05; Fig. 1).
Figure 1. The cytotoxic activity of supernatants of control mac-
rophages (K), obtained from hamsters bearing transplantable
melanotic (Ma) and amelanotic (Ab) melanomas and IL-10 and
NO content in these supernatants. The values are the means
± SD of 6–10 experiments done in triplicate. For each experi-
ment 3–4 animals were used in each group. Statistical analysis
by nonparametric Mann-Whitney U test: *statistically significant
(p < 0.05) increase of IL-10 secretion by Ma macrophages in
comparison with control macrophages, **statistically significant
decrease of IL-10 secretion by Ab macrophages in comparison
with control macrophages (p < 0.05) and Ma macrophages
(p < 0.001), ***statistically significant increase of NO secretion
by Ab macrophages in comparison with control macrophages
(p < 0.05), ****statistically significant increase of Ab macrophag-
es cytotoxicity in comparison with Ma macrophages (p < 0.01).
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DISCUSSION
The results, indicating that macrophages from
animals bearing two transplantable melanoma lines
(compared with control macrophages) secrete dif-
ferent amounts of IL-10, seem to show that a spon-
taneous alteration of a native melanotic line into an
amelanotic form accompanied by tumour progres-
sion is connected with changes in the secretion of
IL-10 by peritoneal macrophages.
These results show that a changed phenotype and
higher tumorogenicity of melanomas is connected
with a statistically significant decrease of IL-10 se-
cretion by macrophages. This may suggest that the
secretion of IL-10 by macrophages depends on the
biological features of melanomas. This observation
is in agreement with our ealier investigations con-
cerning the secretion of other cytokines by macroph-
ages from animals bearing two transplantable mela-
noma lines [13].
Simultaneously during this study we observed
that macrophages from animals with  the amelanotic
melanoma line with a higher growth rate, secreting
less IL-10 had a higher cytotoxic activity against these
melanoma line cells.
The decrease of IL-10 secretion by macrophages
from animals with the amelanotic line could explain
the higher cytotoxic activity of these macrophages
as an effect of the decrease of the suppressor factor
— IL-10 secreted by macrophages — the main type
of cells producing this cytokine [6] .
This observation seems to agree with other stud-
ies, which suggest that IL-10 inhibits the antitumour
activity of macrophages [16, 19, 21].
Simultaneously we observed a pronounced in-
crease in NO secretion by macrophages from animals
with amelanotic melanoma and the decrease in IL-10
secretion, which can explain the increase in the cyto-
toxic activity of these macrophages and on the other
hand confirm the results of other authors, indicating
that IL-10 inhibits NO production [21, 24, 26]; as our
results indicate, the decrease of IL-10 secretion could
be the cause of the higher NO secretion.
It should be underlined that this interpretation
of the obtained results can refer only to  macroph-
ages from hamsters with the transplantable amel-
anotic melanoma line.
Although macrophages from animals bearing the
native melanotic melanoma line, with a lower growth
rate and a higher degree of differentiation, secreted
more IL-10 and NO than the control macrophages,
they did not increase significantly their cytotoxicity
against these melanoma cells.
We may say that in the case of the melanotic line
the IL-10 did not inhibit NO secretion because the
increase of its content was accompanied by an in-
crease in IL-10 secretion.
Therefore, the results mentioned above show that
IL-10 does not always inhibit  NO secretion. This ob-
servation is in agreement with Kundu et al. [16], who
report that IL-10 does not inhibit NO production by
melanoma cells but induces NO secretion and in this
way inhibits the growth of these tumour cells. But
such a relationship has not been described so far for
macrophages.
Furthermore, our present investigations seem to
indicate that peritoneal macrophages from animals
bearing transplantable melanomas react nonuni-
formly to the kind of transplanted melanoma line
and their cytotoxicity does not always depend on
NO secretion.
In the interpretation of the biological implications
of this problem Shearer’s suggestion [23] — that
there are subpopulations of macrophages which
secrete cytokines enhancing the immunobiological
properties of these cells, and subpopulations secret-
ing IL-10 which suppress  the immunological reac-
tion — is helpful.
Bondenson et al. [5] also consider that the secre-
tion by macrophages of cytokines inducing or inhib-
iting immunological reactions is regulated by differ-
ent mechanisms. Besides, these authors suggested
that even single macrophages can influence each
other’s cytokine secretion by paracrine or autocrine
interactions.
Depending on the biological features of trans-
plantable melanomas, the proportions of particular
macrophage populations, including those secreting
IL-10, might conceivably change. Our earlier study
indicated changes in the heterogeneity of macroph-
ages from hamsters with transplantable melanomas
[11, 12].
We should also consider the results of other authors,
who indicated that IL-10 can inhibit macrophage differ-
entiation by enhancing their apoptosis [8, 26].
Thus, we could assume that macrophages from
animals bearing the melanotic melanoma line, which
secrete more IL-10, undergo apoptosis faster and that
is why they are less active during the cytotoxic reac-
tion than macrophages from animals with the
amelanotic form, which secrete less IL-10. This prob-
lem still requires further studies.
To sum up the results, it may be concluded that
the phenotype features of melanomas, connected
with their progression, conspicuously modify the
131
Krystyna Kozłowska et al., IL-10, NO in the macrophages’ cytotoxicity
secretory activity of macrophages as regards  IL-10
and NO secretion.
We also observed that with melanoma progres-
sion the changed IL-10 secretion by macrophages
was inversely correlated with the cytotoxic activity
of macrophages, although it was not correlated with
NO secretion.
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